← boardnext 2026-10next 2027-08-20next 2028-07
ARWR
Arrowhead Pharmaceuticalsdistress 3/10 · well-funded / low risk$87.25-2%today-2% from 52w high
Metabolic / Obesity 2Nephrology 1Neurology 1Respiratory 1
Lead: Severe Hypertriglyceridemia · target APOC3
Revenue
$338M
Liquidity
$1784M
Runway
—
Shares 1y
+2%
Price & events
+25.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
+22.2%
1W
+9.2%
1M
+17.3%
3M
+30.1%
6M
+448.0%
1Y
+203.1%
2Y
+27.6%
5Y
+16.6%
All
Overview
- Market Cap
- $12.29B
- Volume
- 190.22K
- 52 Week Range
- $14.71 – $88.70
- Total Shares
- 140.86M
- Float Shares
- 122.78M
- Short %
- 8.34%
- % Held by Insiders
- 3.68%
- % Held by Institutions
- 88.91%
- RVOL
- 0.07x
- Beta
- 1.26
Pipeline stages · 3 programs
ARO-RAGE
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zodasiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Plozasiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 17 trials · 10 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 1/2 | ARO-ALK7 | Obesity, Diabetes Mellitus, Type 2 | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 1/2 | ARO-DUX4 for Injection | Facio-Scapulo-Humeral Dystrophy | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 1/2 | ARO-DM1 Intravenous (IV) Infusion, ARO-DM1 subcutaneous (SC) injection | Myotonic Dystrophy 1 | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 1/2 | ARO-MAPT-SC | Alzheimer Disease, Alzheimer Disease, Early Onset | — | recruiting |
| 2027-08-20 Estimated 50% readout ~2027-11-03 | Phase 3 | zodasiran Injection | Homozygous Familial Hypercholesterolemia | — | recruiting |
Show all 17 trials · 12 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09-17 Estimated 50% readout ~2027-11-01 | Phase 1/2 | ARO-INHBE, Tirzepatide | Obesity | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | ARO-RAGE | Asthma | — | recruiting |
| 2028-07 Estimated 50% readout ~2028-09-14 | Phase 3 | Plozasiran Injection | Hypertriglyceridemia | — | recruiting |
| 2028-07 Estimated 50% readout ~2028-09-14 | Phase 3 | Zodasiran | Homozygous Familial Hypercholesterolemia | — | not yet recruiting |
| 2029-03 Estimated 50% readout ~2029-05-15 | Phase 3 | Plozasiran | Severe Hypertriglyceridemia | — | recruiting |
| 2026-06 | Phase 3 | Plozasiran Injection | Severe Hypertriglyceridemia | 311 | active not recruiting |
| 2026-06 | Phase 3 | Plozasiran Injection | Severe Hypertriglyceridemia | 446 | active not recruiting |
| 2026-06 | Phase 1/2 | ARO-DIMERPA | Hyperlipidemia; Mixed | 78 | recruiting |
| 2025-09-22 | Phase 2 | ARO-APOC3 | Dyslipidemias | 418 | completed |
| 2025-04-16 | Phase 1/2 | ARO-RAGE | Asthma | 127 | completed |
| 2025-03-31 | Phase 1 | ARO-CFB | IgA Nephropathy | 49 | completed |
| 2025-03 | Phase 1 | ARO-SOD1 Injection | Amyotrophic Lateral Sclerosis | 0 | withdrawn |
Catalyst news & presentations · 1
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (1)
- REDEMPLOPLOZASIRAN SODIUM2025 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $96 (+10% upside) · 11 analysts
- 2026-07-17JP MorganOverweight
- 2026-07-14StifelBuy
- 2026-07-01HC Wainwright & Co.Buy
- 2026-06-30Chardan CapitalBuy
- 2026-06-17Leerink PartnersMarket Perform
- 2026-05-13BernsteinMarket Perform
Competitors — APOC3
- none identified
Recent news
- 2026-07-22Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $101.6, Implies 36% Upside - TradingView
- 2026-07-22Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send? - TradingKey
- 2026-07-22The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
- 2026-07-22ARWR Stock Climbs As EU REDEMPLO Win Fuels Bullish Targets - StocksToTrade
- 2026-07-22Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight - AlphaStreet
- 2026-07-22Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released - TechStock²
- 2026-07-22Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization - Yahoo Finance UK
- 2026-07-22Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Positive Trial Results - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.